NASDAQ:RGNX - Regenxbio Stock Price, Forecast & News

Regenxbio trades on the NASDAQ under the ticker symbol "RGNX."

Regenxbio Inc (NASDAQ:RGNX) released its quarterly earnings data on Tuesday, November, 5th. The biotechnology company reported ($0.94) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.91) by $0.03. The biotechnology company had revenue of $14.70 million for the quarter, compared to the consensus estimate of $7.46 million. Regenxbio had a negative return on equity of 18.74% and a negative net margin of 99.57%. Regenxbio's revenue for the quarter was up 177.0% compared to the same quarter last year. During the same period last year, the company earned ($0.56) EPS. View Regenxbio's Earnings History.

Regenxbio is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Regenxbio.

Regenxbio will be holding an earnings conference call on Wednesday, February 26th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

6 equities research analysts have issued 1-year price objectives for Regenxbio's shares. Their forecasts range from $37.00 to $150.00. On average, they anticipate Regenxbio's stock price to reach $77.50 in the next year. This suggests a possible upside of 54.2% from the stock's current price. View Analyst Price Targets for Regenxbio.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regenxbio in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Regenxbio.

Headlines about RGNX stock have trended neutral on Tuesday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Regenxbio earned a coverage optimism score of 0.4 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 9.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Regenxbio.

Some companies that are related to Regenxbio include BioNTech (BNTX), Moderna (MRNA), argenx (ARGX), Repligen (RGEN), Acceleron Pharma (XLRN), China Biologic Products (CBPO), bluebird bio (BLUE), Spark Therapeutics (ONCE), Adaptive Biotechnologies (ADPT), Ablynx (ABLYF), Momenta Pharmaceuticals (MNTA), Iovance Biotherapeutics (IOVA), Crispr Therapeutics (CRSP), Halozyme Therapeutics (HALO) and Allogene Therapeutics (ALLO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Regenxbio investors own include NVIDIA (NVDA), AbbVie (ABBV), Visa (V), Amarin (AMRN), Exelixis (EXEL), Gilead Sciences (GILD), Square (SQ), Immunomedics (IMMU), Voyager Therapeutics (VYGR) and Alibaba Group (BABA).

Regenxbio's stock is owned by many different of retail and institutional investors. Top institutional shareholders include State Street Corp (5.10%), UBS Group AG (1.78%), Credit Suisse AG (1.38%), Kam Lawrence (1.27%), Geode Capital Management LLC (1.25%) and Korea Investment CORP (1.24%). Company insiders that own Regenxbio stock include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Luke M Beshar, Olivier Danos, Patrick J Christmas, Stephen Yoo and Vittal Vasista. View Institutional Ownership Trends for Regenxbio.

RGNX stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Rafferty Asset Management LLC, Bank of New York Mellon Corp, Citigroup Inc., SG Americas Securities LLC, P.A.W. Capital Corp, AQR Capital Management LLC and Franklin Resources Inc.. Company insiders that have sold Regenxbio company stock in the last year include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Olivier Danos, Patrick J Christmas and Vittal Vasista. View Insider Buying and Selling for Regenxbio.

RGNX stock was acquired by a variety of institutional investors in the last quarter, including Kam Lawrence, UBS Group AG, Goldman Sachs Group Inc., Barclays PLC, Parkman Healthcare Partners LLC, Panagora Asset Management Inc., Rhenman & Partners Asset Management AB and Cubist Systematic Strategies LLC. View Insider Buying and Selling for Regenxbio.

Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of RGNX stock can currently be purchased for approximately $50.25.

Regenxbio has a market capitalization of $1.85 billion and generates $218.51 million in revenue each year. The biotechnology company earns $99.94 million in net income (profit) each year or $2.38 on an earnings per share basis. Regenxbio employs 192 workers across the globe.View Additional Information About Regenxbio.

The official website for Regenxbio is http://www.regenxbio.com/.

Regenxbio's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-552-8181 or via email at [email protected]